Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$9.48
-1.7%
$9.86
$5.67
$13.50
$391.45M0.6581,653 shs668,223 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.39
-4.1%
$1.95
$1.30
$12.33
$53.18M1.31802,729 shs2.58 million shs
SiBone stock logo
SIBN
SiBone
$18.78
+1.8%
$18.17
$11.70
$20.05
$785.81M0.93392,035 shs294,940 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$31.02
+0.6%
$28.96
$26.00
$42.25
$440.99M1.31221,719 shs66,258 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-1.66%-1.15%-14.90%+2.05%+69.29%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-4.14%-3.14%-38.22%-13.66%-85.02%
SiBone stock logo
SIBN
SiBone
+1.84%+1.73%-1.68%+40.46%+38.60%
Surmodics, Inc. stock logo
SRDX
Surmodics
+0.58%+3.45%+6.23%+8.88%-26.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.5207 of 5 stars
3.51.00.04.20.01.70.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.899 of 5 stars
3.31.00.04.42.90.01.3
SiBone stock logo
SIBN
SiBone
4.0478 of 5 stars
2.55.00.03.32.02.50.6
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1985 of 5 stars
3.33.00.03.40.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.0047.68% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$8.80533.09% Upside
SiBone stock logo
SIBN
SiBone
3.00
Buy$22.5019.81% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
2.50
Moderate Buy$43.0038.62% Upside

Current Analyst Ratings Breakdown

Latest ANGO, SIBN, INO, and SRDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/30/2025
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$283.32M1.36$4.21 per share2.25$5.13 per share1.85
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K180.07N/AN/A$1.90 per share0.73
SiBone stock logo
SIBN
SiBone
$167.18M4.79N/AN/A$3.98 per share4.72
Surmodics, Inc. stock logo
SRDX
Surmodics
$126.08M3.52$0.31 per share99.68$8.33 per share3.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$184.35M-$1.01N/AN/AN/A-14.61%-3.73%-2.43%7/15/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$11.54M-$1.39N/A38.78N/A-16.34%-7.10%-4.77%7/30/2025 (Estimated)

Latest ANGO, SIBN, INO, and SRDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
SiBone stock logo
SIBN
SiBone
-$0.19N/AN/AN/A$48.12 millionN/A
7/30/2025Q3 2025
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.21N/AN/AN/A$28.04 millionN/A
7/15/2025Q4 2025
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$0.13N/AN/AN/A$74.26 millionN/A
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/5/2025Q1 2025
SiBone stock logo
SIBN
SiBone
-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million
4/30/2025Q2 2025
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.06-$0.13-$0.07-$0.36$32.23 million$28.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.21
1.40
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
2.63
2.63
SiBone stock logo
SIBN
SiBone
0.21
8.53
7.26
Surmodics, Inc. stock logo
SRDX
Surmodics
0.27
5.14
3.99

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
SiBone stock logo
SIBN
SiBone
98.11%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.40%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
SiBone stock logo
SIBN
SiBone
4.00%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
76040.61 million38.41 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million35.83 millionOptionable
SiBone stock logo
SIBN
SiBone
35042.62 million40.91 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
45014.30 million13.03 millionOptionable

Recent News About These Companies

Q1 Earnings Estimate for Surmodics Issued By Zacks Research
A Look at Surmodics's Upcoming Earnings Report
Surmodics publishes TRANSCEND trial data
Barrington Sticks to Their Hold Rating for SurModics (SRDX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AngioDynamics stock logo

AngioDynamics NASDAQ:ANGO

$9.48 -0.16 (-1.66%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$9.43 -0.05 (-0.53%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.39 -0.06 (-4.14%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.01 (+0.43%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

SiBone stock logo

SiBone NASDAQ:SIBN

$18.78 +0.34 (+1.84%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$18.34 -0.44 (-2.32%)
As of 06:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Surmodics stock logo

Surmodics NASDAQ:SRDX

$31.02 +0.18 (+0.58%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$31.02 0.00 (-0.02%)
As of 07/10/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.